An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
CytRx to Hold Town Hall for Stockholders on Thursday, January 20th
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
CytRx Corporation (OTCQB: CYTR) will hold a town hall for stockholders on January 20, 2022, at 4:30 PM Eastern. The event will be led by new CEO Dr. Stephen Snowdy and will include a question-and-answer session. Access to the town hall will be provided here. Following the event, a recording will be available on the company's website.
Positive
Dr. Stephen Snowdy appointed as new CEO, potentially bringing fresh leadership and vision.
Upcoming town hall offers stockholders direct engagement with management.
Negative
None.
Town Hall to be Led by New CEO Dr. Stephen Snowdy
LOS ANGELES--(BUSINESS WIRE)--
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it will hold a town hall for stockholders on Thursday, January 20, 2022 at 4:30 PM Eastern. The town hall will be led by the Company’s Chief Executive Officer, Dr. Stephen Snowdy, and include a question-and-answer session. The town hall can be accessed here.
A recording of the town hall will be available on CytRx's website under the News & Events section following the event.
About CytRx
CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. CytRx Corporation’s website is www.cytrx.com.
